Study Supports Biomarker Assay for Diagnosis of Acute Heart Failure
News Mar 23, 2018 | Original story from Massachusetts General Hospital
A multi-institutional study supports the value of a biomarker to accurately diagnose or rule out acute heart failure in patients seen for shortness of breath at hospital emergency departments. The report published in the Journal of the American College of Cardiology also validates the use of age-adjusted thresholds of the protein NT-proBNP to diagnose heart failure in a wide range of such patients.
“Since we did the first U.S.-based studies of NT-proBNP for the identification or exclusion of heart failure, as well as for establishing the risk of bad outcomes, its use has been incorporated into diagnostic guidelines internationally,” says James Januzzi Jr., MD, of the Massachusetts General Hospital Division of Cardiology, who led the study. “But over the past 15 years, the characteristics of patients with heart failure have changed – they tend to be older, are more likely to be women and to have additional complications – making a contemporary re-assessment of the assay’s performance necessary.
NT-proBNP (N-terminal pro-brain natriuretic peptide) and a related protein called BNP (B-type natriuretic peptide) are both produced when the cardiac muscle is under stress. One of the earliest studies of the value of NT-proBNP testing, conducted in the MGH Emergency Department, suggested age-based diagnostic cutoffs for diagnosis of acute heart failure – 450 pg/ml for patients under 50, 900 pg/ml for those 50 to 75, and 1,800 pg/ml for those over 75. An NT-proBNP level of 300 or below appeared to rule out acute heart failure no matter the patient’s age.
Use of those cutoffs was supported by a larger, multi-institutional trial, but while they have been largely adopted at hospitals worldwide, the only NT-proBNP diagnostic cutoffs approved by the U.S. Food and Drug Administration (FDA) are 125 pg/ml for patients under 75 and 450 pg/ml for those 75 and older – levels designed for use in conjunction with outpatient treatment. The current study, conducted by the Baim Institute for Clinical Research, and led by Januzzi, was designed both to validate the emergency-care-based cutoffs and to determine whether they remain useful for assessment of the current population of patients with heart failure.
Conducted in 2015 and 2016 at 19 sites in the U.S. and Canada, the study enrolled 1,461 adult patients who had come to hospital emergency departments with shortness of breath or other breathing difficulties. Blood samples to be measured for NT-proBNP levels were taken upon study enrollment, and determination of the presence of acute heart failure – separate from the clinical diagnosis that guided participants’ care – was made by clinicians blinded to individual participants’ NT-proBNP levels. Overall, 277 patients – 19 percent of total study enrollment – were determined to have acute heart failure.
Comparison of participants’ NT-proBNP levels with their eventual diagnoses supported the usefulness of the age-based cutoff levels and that a level below 300 strongly excluded a heart failure diagnosis. These results were consistent across all groups of participants, no matter their age, gender, racial or ethnic background or the presence of conditions like obesity or kidney disease.
“We found no specific population in which the test did not perform well, and what was most striking to me – as someone who has been working with NT-proBNP since the early 2000s – was how consistent these results were with those of prior studies,” says Januzzi, who is the Hutter Family Professor of Medicine in the Field of Cardiology at Harvard Medical School. “Given the changes in the types of patients with heart failure we see today, it’s quite remarkable how reliable this test is.”
Januzzi and his colleague expect their results will extend the use of age-based NT-proBNP cutoffs even further, which by allowing faster and more accurate diagnosis or exclusion of heart failure should lead to better patient outcomes. They also anticipate FDA approval of the age-based cutoffs for emergency department diagnosis.
This article has been republished from materials provided by Massachusetts General Hospital. Note: material may have been edited for length and content. For further information, please contact the cited source.
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE